{"id":"disease-modifying-antirheumatic-drug","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (including serious infections)"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Bone marrow suppression"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_fixedAt":"2026-03-30T13:37:20.493631","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DMARDs work through various mechanisms including immunosuppression, cytokine inhibition, and modulation of T-cell or B-cell function to reduce joint inflammation and slow radiographic progression. Unlike NSAIDs and corticosteroids that primarily manage symptoms, DMARDs target the disease pathology itself and can induce remission or low disease activity. Pfizer's DMARD pipeline includes both conventional synthetic DMARDs and biologic agents targeting specific immune pathways.","oneSentence":"Disease-modifying antirheumatic drugs (DMARDs) suppress the underlying immune-mediated inflammatory processes that drive rheumatoid arthritis and other autoimmune conditions.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:56.022Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Other autoimmune inflammatory conditions (specific indication dependent on individual agent)"}]},"_fixedFields":["pubmed(1752)"],"trialDetails":[{"nctId":"NCT07489326","phase":"","title":"The SetPoint System Safety & Performance Post-Approval Study","status":"NOT_YET_RECRUITING","sponsor":"SetPoint Medical Corporation","startDate":"2026-04-15","conditions":"Rheumatoid Arthritis","enrollment":150},{"nctId":"NCT07484113","phase":"PHASE1","title":"IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-05","conditions":"cGVHD","enrollment":10},{"nctId":"NCT06671483","phase":"PHASE3","title":"A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-03-03","conditions":"Psoriatic Arthritis","enrollment":1088},{"nctId":"NCT07436494","phase":"","title":"Coronavirus Anxiety in Patients Using Biologic vs Conventional DMARDs","status":"COMPLETED","sponsor":"Bursa City Hospital","startDate":"2020-10-15","conditions":"COVID-19, Anxiety, Rheumatic Diseases","enrollment":200},{"nctId":"NCT06641076","phase":"PHASE3","title":"Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug","status":"ACTIVE_NOT_RECRUITING","sponsor":"MoonLake Immunotherapeutics AG","startDate":"2024-10-15","conditions":"Arthritis, Psoriatic","enrollment":960},{"nctId":"NCT07417995","phase":"","title":"A Study of Clinical and Immune Responses to Sequential Biologic Therapies in Psoriatic Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Royal United Hospitals Bath NHS Foundation Trust","startDate":"2026-03","conditions":"Psoriasis Arthritis","enrollment":400},{"nctId":"NCT07423533","phase":"PHASE2","title":"Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2026-02","conditions":"Rheumatoid Arthritis","enrollment":450},{"nctId":"NCT06382051","phase":"NA","title":"Modifying PEST for Psoriatic Arthritis Screening","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-01-23","conditions":"Plaque Psoriasis, Psoriatic Arthritis","enrollment":502},{"nctId":"NCT06764693","phase":"","title":"An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-01-31","conditions":"Psoriatic Arthritis","enrollment":1200},{"nctId":"NCT06276998","phase":"PHASE3","title":"A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lynk Pharmaceuticals Co., Ltd","startDate":"2023-12-12","conditions":"Rheumatoid Arthritis","enrollment":430},{"nctId":"NCT07335952","phase":"PHASE2","title":"Proximod, a Selective Sphingosine-1-phosphate Receptor 1 Modulator in Patients With Moderate-to-severe Active Rheumatoid Arthritis: a Double-blind, Randomised, Placebo-controlled, Phase 2 Trial.","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2024-09-02","conditions":"Rheumatoid Arthritis","enrollment":179},{"nctId":"NCT05671497","phase":"PHASE2, PHASE3","title":"The Effect of Cilostazol on Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":70},{"nctId":"NCT05421442","phase":"","title":"A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-06-13","conditions":"Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)","enrollment":38396},{"nctId":"NCT05413044","phase":"","title":"A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-07-01","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis","enrollment":140706},{"nctId":"NCT05879419","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2023-05-23","conditions":"Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis","enrollment":2005},{"nctId":"NCT06072768","phase":"PHASE2","title":"Dynamic Treatment Regiments for Glucocorticoid Tapering","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2023-03-09","conditions":"Rheumatoid Arthritis","enrollment":200},{"nctId":"NCT04908202","phase":"PHASE3","title":"A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-07-13","conditions":"Psoriatic Arthritis","enrollment":670},{"nctId":"NCT06671054","phase":"PHASE2","title":"A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis","status":"RECRUITING","sponsor":"SynAct Pharma Aps","startDate":"2024-10-01","conditions":"Rheumatoid Arthritis (RA)","enrollment":240},{"nctId":"NCT05413759","phase":"NA","title":"RhEumatoid Arthritis MEDIcation Adherence","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2022-06-28","conditions":"Rheumatoid Arthritis","enrollment":200},{"nctId":"NCT03104400","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-04-27","conditions":"Psoriatic Arthritis","enrollment":1705},{"nctId":"NCT01394276","phase":"","title":"An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-05","conditions":"Rheumatoid Arthritis","enrollment":322},{"nctId":"NCT03104374","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-05-01","conditions":"Psoriatic Arthritis","enrollment":642},{"nctId":"NCT06497491","phase":"PHASE3","title":"An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still's Disease","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2023-12-12","conditions":"Still's Disease Adult Onset","enrollment":118},{"nctId":"NCT03414502","phase":"PHASE3","title":"Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2007-12-10","conditions":"Rheumatoid Arthritis","enrollment":400},{"nctId":"NCT03675308","phase":"PHASE3","title":"A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2019-03-25","conditions":"Psoriatic Arthritis","enrollment":964},{"nctId":"NCT05198310","phase":"PHASE2","title":"Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor","status":"COMPLETED","sponsor":"Kiniksa Pharmaceuticals, Ltd.","startDate":"2021-12-14","conditions":"Arthritis, Rheumatoid","enrollment":145},{"nctId":"NCT04908189","phase":"PHASE3","title":"A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-07-15","conditions":"Psoriatic Arthritis","enrollment":729},{"nctId":"NCT05572567","phase":"","title":"Study to Evaluate Safety and Effects of Tofacitinib and Biologic Disease Modifying Antirheumatic Drugs in People Treated for Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-10-10","conditions":"Arthritis, Rheumatoid","enrollment":1972},{"nctId":"NCT03906136","phase":"PHASE3","title":"AScalate: Treat-to-target in Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-04","conditions":"Axial Spondyloarthritis","enrollment":304},{"nctId":"NCT01247766","phase":"","title":"Safety Study of Abatacept to Treat Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-12-31","conditions":"Rheumatoid Arthritis","enrollment":6367},{"nctId":"NCT03336281","phase":"","title":"A Study to Characterize Profile of Participant With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab","status":"COMPLETED","sponsor":"Janssen Cilag S.A.S.","startDate":"2017-04-25","conditions":"Psoriatic Arthritis","enrollment":221},{"nctId":"NCT06753565","phase":"PHASE2","title":"L-carnitine Supplementation in Rheumatoid Arthritis Patients","status":"RECRUITING","sponsor":"German University in Cairo","startDate":"2024-12-31","conditions":"Rheumatoid Arthritis (RA)","enrollment":60},{"nctId":"NCT06011889","phase":"PHASE2, PHASE3","title":"Study of the Efficacy and Safety of Etanercept Treatment in Patients With SAPHO Syndrome","status":"RECRUITING","sponsor":"National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland","startDate":"2024-09-04","conditions":"SAPHO Syndrome","enrollment":60},{"nctId":"NCT01932372","phase":"","title":"Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-07-26","conditions":"Rheumatoid Arthritis","enrollment":9968},{"nctId":"NCT03660059","phase":"PHASE3","title":"A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2018-09-27","conditions":"Rheumatoid Arthritis (RA)","enrollment":385},{"nctId":"NCT05437419","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, and PK of Oral Doses of TCK-276 in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Teijin America, Inc.","startDate":"2022-08-10","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT04888585","phase":"PHASE2","title":"Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)","status":"TERMINATED","sponsor":"AbbVie","startDate":"2021-06-23","conditions":"Rheumatoid Arthritis (RA)","enrollment":473},{"nctId":"NCT05291819","phase":"NA","title":"Imaging Treat-to-target Strategy vs Conventional Treat-to-target Strategy in Psoriatic Arthritis","status":"RECRUITING","sponsor":"Diakonhjemmet Hospital","startDate":"2022-03-14","conditions":"Psoriatic Arthritis","enrollment":202},{"nctId":"NCT04347798","phase":"","title":"IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2020-11-01","conditions":"Covid-19 Infection, Rheumatoid Arthritis, Psoriatic Arthritis","enrollment":773},{"nctId":"NCT06565273","phase":"PHASE2","title":"Study to Investigate the Efficacy, Safety, and Tolerability of FBL-MTX in Patients With Rheumatoid Arthritis","status":"RECRUITING","sponsor":"SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd","startDate":"2024-07-24","conditions":"Rheumatoid Arthritis","enrollment":40},{"nctId":"NCT04725422","phase":"","title":"CHronic Nonbacterial Osteomyelitis International Registry","status":"RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2018-08-01","conditions":"Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis","enrollment":2000},{"nctId":"NCT03086343","phase":"PHASE3","title":"A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-05-09","conditions":"Rheumatoid Arthritis (RA)","enrollment":657},{"nctId":"NCT02451748","phase":"PHASE4","title":"IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2015-08","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT03652961","phase":"PHASE4","title":"Rheumatoid Arthritis Memory B Cells and Abatacept","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2019-06-02","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT06475508","phase":"PHASE3","title":"Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2023-02-13","conditions":"Rheumatoid Arthritis","enrollment":465},{"nctId":"NCT06417138","phase":"","title":"Comparative Effectiveness of Different Drugs Used to tr€at Patients in Rheumatoid Arthritis Saudi Database (RASD)\"","status":"RECRUITING","sponsor":"Umm Al-Qura University","startDate":"2023-12-15","conditions":"Rheumatoid Arthritis RA","enrollment":800},{"nctId":"NCT06306339","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)","status":"UNKNOWN","sponsor":"ImmuneMed, Inc.","startDate":"2024-03","conditions":"Moderate to Severe Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT04749160","phase":"","title":"Smart Marker Annunciating Response to Rheumatologic Treatments SMART²T","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2021-06-04","conditions":"Rheumatoid Arthritis","enrollment":26},{"nctId":"NCT03970837","phase":"PHASE3","title":"Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-06-05","conditions":"Arthritis, Rheumatoid","enrollment":1764},{"nctId":"NCT03155347","phase":"PHASE3","title":"An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-08-02","conditions":"Rheumatoid Arthritis","enrollment":340},{"nctId":"NCT04645420","phase":"NA","title":"Molecular Effects of Apremilast in the Synovium of Psoriatic Arthritis Patients","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2020-11-12","conditions":"Psoriatic Arthritis","enrollment":19},{"nctId":"NCT05154370","phase":"","title":"China National Registry of Neuro-Inflammatory Diseases","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2021-12-15","conditions":"Multiple Sclerosis, NMO Spectrum Disorder, Clinically Isolated Syndrome","enrollment":10000},{"nctId":"NCT04134728","phase":"PHASE3","title":"Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-10-31","conditions":"Arthritis, Rheumatoid","enrollment":550},{"nctId":"NCT04226131","phase":"NA","title":"MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics","status":"COMPLETED","sponsor":"Duke University","startDate":"2020-09-09","conditions":"Rheumatoid Arthritis, Healthy Controls","enrollment":21},{"nctId":"NCT01844518","phase":"PHASE3","title":"Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-08-30","conditions":"Active Polyarticular Juvenile Idiopathic Arthritis","enrollment":219},{"nctId":"NCT02720523","phase":"PHASE2, PHASE3","title":"A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03-22","conditions":"Rheumatoid Arthritis","enrollment":197},{"nctId":"NCT02675426","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-17","conditions":"Rheumatoid Arthritis","enrollment":661},{"nctId":"NCT05683769","phase":"","title":"microRNA in Erosive Hand Osteoarthritis and Psoriatic Arthritis","status":"COMPLETED","sponsor":"University of Siena","startDate":"2018-09-01","conditions":"Erosive Osteoarthritis, Psoriatic Arthritis","enrollment":150},{"nctId":"NCT02706847","phase":"PHASE3","title":"A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03-15","conditions":"Rheumatoid Arthritis","enrollment":499},{"nctId":"NCT01581294","phase":"","title":"The Norwegian Antirheumatic Drug Register","status":"RECRUITING","sponsor":"Diakonhjemmet Hospital","startDate":"2012-04","conditions":"Inflammatory Joint Diseases","enrollment":15000},{"nctId":"NCT04434885","phase":"","title":"Axial Involvement in Psoriatic Arthritis Cohort","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2021-07-01","conditions":"Psoriatic Arthritis","enrollment":400},{"nctId":"NCT01307423","phase":"PHASE3","title":"Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-12-09","conditions":"Psoriatic Arthritis","enrollment":529},{"nctId":"NCT03419143","phase":"","title":"Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-03-02","conditions":"Psoriatic Arthritis (PsA)","enrollment":190},{"nctId":"NCT05165771","phase":"PHASE2","title":"Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment","status":"WITHDRAWN","sponsor":"Gilead Sciences","startDate":"2022-07","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT01881308","phase":"PHASE4","title":"Assessing Withdrawal of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Diakonhjemmet Hospital","startDate":"2013-06-17","conditions":"Rheumatoid Arthritis","enrollment":320},{"nctId":"NCT01885078","phase":"PHASE3","title":"An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-06-27","conditions":"Rheumatoid Arthritis","enrollment":2877},{"nctId":"NCT01146652","phase":"PHASE3","title":"Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-06-21","conditions":"Rheumatoid Arthritis","enrollment":2023},{"nctId":"NCT02353221","phase":"","title":"CPMC Early Undifferentiated Arthritis Registry","status":"COMPLETED","sponsor":"California Pacific Medical Center Research Institute","startDate":"2015-01","conditions":"Early Undifferentiated Arthritis","enrollment":54},{"nctId":"NCT05078502","phase":"NA","title":"Role of Vitamin D3 Supplementation With Conventional Synthetic Disease Modifying Antirheumatic Drugs(csDMARD) in Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2021-06-01","conditions":"Rheumatoid Arthritis","enrollment":58},{"nctId":"NCT05119452","phase":"NA","title":"Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2022-03","conditions":"Rheumatoid Arthritis","enrollment":85},{"nctId":"NCT01490450","phase":"PHASE2","title":"Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2011-12","conditions":"Arthritis, Psoriatic","enrollment":165},{"nctId":"NCT03131661","phase":"","title":"A Study in Participants With a Newly Confirmed Diagnosis of Spondyloarthritis (SpA) Who Are New to Conventional, Targeted and Biological DMARDs","status":"COMPLETED","sponsor":"Janssen-Cilag S.p.A.","startDate":"2017-06-09","conditions":"Spondyloarthritis, Axial and Peripheral","enrollment":351},{"nctId":"NCT02955212","phase":"PHASE3","title":"A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-01-03","conditions":"Rheumatoid Arthritis (RA)","enrollment":338},{"nctId":"NCT03910725","phase":"","title":"Electrophysiological Phenotyping Of Patients at Risk of Ventricular Arrhythmia and Sudden Cardiac Death","status":"UNKNOWN","sponsor":"Imperial College London","startDate":"2019-11-21","conditions":"Arrhythmia, Sudden Cardiac Death, Cardiomyopathy, Dilated","enrollment":100},{"nctId":"NCT02930343","phase":"PHASE3","title":"Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy","status":"TERMINATED","sponsor":"Jawaharlal Institute of Postgraduate Medical Education & Research","startDate":"2016-09","conditions":"Rheumatoid Arthritis","enrollment":136},{"nctId":"NCT04973787","phase":"","title":"The Role of Microbiome on Biological Therapy Efficacy in axSpA and RA","status":"UNKNOWN","sponsor":"Universidade Nova de Lisboa","startDate":"2020-08-01","conditions":"Axial Spondyloarthritis, Arthritis, Rheumatoid","enrollment":90},{"nctId":"NCT02627768","phase":"","title":"A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2015-12-17","conditions":"Psoriatic Arthritis","enrollment":991},{"nctId":"NCT02047604","phase":"PHASE2","title":"(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2013-12","conditions":"Rheumatoid Arthritis","enrollment":41},{"nctId":"NCT02873936","phase":"PHASE3","title":"Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-07-27","conditions":"Rheumatoid Arthritis","enrollment":449},{"nctId":"NCT03797872","phase":"PHASE4","title":"Psoriatic Oligoarthritis Intervention With Symptomatic thErapy","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-04-17","conditions":"Psoriatic Arthritis","enrollment":1},{"nctId":"NCT03452501","phase":"","title":"Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients","status":"COMPLETED","sponsor":"Hikma Pharmaceuticals LLC","startDate":"2018-08-26","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Fistulizing Crohn's Disease","enrollment":157},{"nctId":"NCT02799472","phase":"PHASE2","title":"Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-15","conditions":"Arthritis, Rheumatoid","enrollment":39},{"nctId":"NCT04483687","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy","status":"WITHDRAWN","sponsor":"Gilead Sciences","startDate":"2020-12","conditions":"Ankylosing Spondylitis","enrollment":""},{"nctId":"NCT04483700","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy","status":"WITHDRAWN","sponsor":"Gilead Sciences","startDate":"2020-12","conditions":"Ankylosing Spondylitis","enrollment":""},{"nctId":"NCT01764321","phase":"","title":"Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2012-12","conditions":"Rheumatoid Arthritis","enrollment":1723},{"nctId":"NCT03264703","phase":"","title":"Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus ANti-TNF Versus cDMARDs in Real World","status":"COMPLETED","sponsor":"Eisai Korea Inc.","startDate":"2017-09-11","conditions":"Arthritis, Rheumatoid","enrollment":212},{"nctId":"NCT01387802","phase":"","title":"Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-06-29","conditions":"Ankylosing Spondylitis","enrollment":722},{"nctId":"NCT01548768","phase":"PHASE4","title":"RHYTHM (Formerly Escape II Myocardium)","status":"COMPLETED","sponsor":"Columbia University","startDate":"2011-10-10","conditions":"Rheumatoid Arthritis","enrollment":149},{"nctId":"NCT01559038","phase":"","title":"Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-02-16","conditions":"Psoriatic Arthritis","enrollment":483},{"nctId":"NCT03151551","phase":"PHASE4","title":"A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-08-24","conditions":"Psoriatic Arthritis","enrollment":566},{"nctId":"NCT02671838","phase":"NA","title":"A Musculoskeletal Ultrasound Program to Improve Disease Modifying Anti-Rheumatic Drugs Adherence in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2017-01","conditions":"Rheumatoid Arthritis","enrollment":132},{"nctId":"NCT03073109","phase":"","title":"Patient-Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib Or Biological Disease-Modifying Antirheumatic Drugs (DMARDs) In Real Life Conditions","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-03-15","conditions":"Arthritis, Rheumatoid","enrollment":170},{"nctId":"NCT04567576","phase":"","title":"Predictive Factors for COVID-19 in Rheumatology","status":"UNKNOWN","sponsor":"Fundación Santa Fe de Bogota","startDate":"2020-10","conditions":"Rheumatic Diseases, Covid19","enrollment":150},{"nctId":"NCT02557100","phase":"PHASE4","title":"Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-11-19","conditions":"Rheumatoid Arthritis","enrollment":80},{"nctId":"NCT04486027","phase":"","title":"Can Cytokines be Used as an Activation Marker","status":"COMPLETED","sponsor":"Maltepe University","startDate":"2017-04-05","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT01095393","phase":"","title":"National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthritis Treated With Cimzia® or Disease-modifying Antirheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2009-09-01","conditions":"Rheumatoid Arthritis","enrollment":12500},{"nctId":"NCT02349295","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-12-31","conditions":"Psoriatic Arthritis","enrollment":363},{"nctId":"NCT04449224","phase":"","title":"Comparative Effectiveness of Targeted Therapy in RA Patients","status":"UNKNOWN","sponsor":"Hanyang University","startDate":"2020-04-27","conditions":"Rheumatoid Arthritis","enrollment":506},{"nctId":"NCT04390464","phase":"PHASE4","title":"mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2020-05-08","conditions":"COVID19","enrollment":1167},{"nctId":"NCT03348046","phase":"","title":"Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan","status":"COMPLETED","sponsor":"Hikma Pharmaceuticals LLC","startDate":"2017-03-23","conditions":"Rheumatoid Arthritis","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1752,"recentPublications":[{"date":"2026 Apr 1","pmid":"41889659","title":"Treatment patterns of biologic disease-modifying anti-rheumatic drugs in juvenile idiopathic arthritis: a population-based study in Korea.","journal":"Journal of rheumatic diseases"},{"date":"2026 Mar 24","pmid":"41876147","title":"Comparative effectiveness and predictors of remission between adalimumab and ixekizumab in patients with psoriatic arthritis: findings from the 'AIRE' multicentre study.","journal":"RMD open"},{"date":"2026 Mar 17","pmid":"41840229","title":"Monocytes from inflammatory arthritis patients accumulate methotrexate and their transcriptome predicts methotrexate clinical response.","journal":"Cellular and molecular life sciences : CMLS"},{"date":"2026 Mar 16","pmid":"41838419","title":"Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies.","journal":"Rheumatology (Oxford, England)"},{"date":"2026 Mar 13","pmid":"41826585","title":"Investigating the Potential of High Permeation Vesicle-Based Methotrexate Gel for Localized Therapy in Rheumatoid Arthritis.","journal":"Pharmaceutical research"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DMARD, MTX"],"phase":"phase_3","status":"active","brandName":"Disease-modifying antirheumatic drug","genericName":"Disease-modifying antirheumatic drug","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Disease-modifying antirheumatic drugs (DMARDs) suppress the underlying immune-mediated inflammatory processes that drive rheumatoid arthritis and other autoimmune conditions. Used for Rheumatoid arthritis, Other autoimmune inflammatory conditions (specific indication dependent on individual agent).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}